Readoutin 104d
Aragon Pharmaceuticals, Inc. — Apalutamide
Phase 3 primary completion: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Prostatic Neoplasms